"We are going to have lung cancer patients living longer and better:" A new kind of cancer treatment is about to change how we treat the disease (MRK, BMS)

Wikimedia Commons New cancer treatments that harness the body's immune system are ready to go mainstream.  In data presente.....»»

Category: topSource: businessinsiderApr 16th, 2018

AstraZeneca"s immunotherapy drug gets US FDA nod for lung cancer treatment

US FDA granted approval for expanded use of Imfinzi to treat non-small cell lung cancer patients.....»»

Category: topSource: business-standardFeb 17th, 2018

Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

AstraZeneca Files for Label Expansion of Tagrisso in Japan

AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer. AstraZene.....»»

Category: dealsSource: nytNov 28th, 2017

Roche win boosts case for adding chemo to cancer immunotherapy

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients.....»»

Category: topSource: business-standardNov 20th, 2017

A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer (GILD)

AP/Elaine Thompson The FDA approved a second gene therapy to treat cancer, called Yescarta. The therapy works by taking a person's own cells, reprogramming them, and inserting them back into the body.....»»

Category: topSource: businessinsiderOct 19th, 2017

Bankrupt and desperate: Cancer patients are now on Mumbai"s footpaths

4 in 10 patients living on street from Bihar, 92% sought treatment before coming to Tata Hospital.....»»

Category: topSource: business-standardSep 4th, 2017

Hormone treatment for prostate cancer tied to heart risks

Results can be particularly important for prostate patients who have risk factors for heart disease.....»»

Category: topSource: business-standardSep 2nd, 2017

A non-invasive way to treat brain tumours

After treating 300 cancer patients from across the world over the past decade, Bengaluru-based SBF Healthcare & Research Centre (SHRC) has formally announced a treatment based on a new technolog........»»

Category: topSource: thehindubusinesslineJul 31st, 2017

New cancer treatments that are programmed to treat a person"s specific tumor just passed 2 early tests (MRK, BMY, SAN, LLY)

 LONDON, July 5 (Reuters) - A novel class of personalised cancer vaccines, tailored to the tumours of individual patients, kept disease in check in two early-stage clinical trials, .....»»

Category: topSource: businessinsiderJul 5th, 2017

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Category: blogSource: 247wallstApr 17th, 2018

New Drug Combinations Improve Survival in Lung Cancer

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Category: smallbizSource: wsjApr 17th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets

The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement......»»

Category: topSource: marketwatchApr 16th, 2018

We"re about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated (MRK, BMS, RHHBY)

Reuters On Monday, three big players in the growing field of cance.....»»

Category: topSource: businessinsiderApr 14th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

Merck Moves Ahead With Late-Stage Trial Win

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint......»»

Category: blogSource: 247wallstApr 9th, 2018

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval

Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients. The FDA approved the Boulder-based .....»»

Category: topSource: bizjournalsApr 6th, 2018